Interleukin 21 (IL21) is an immune-stimulating cytokine that has demonstrated antitumour activity in preclinical models and has recently entered clinical trials. Here, the authors discuss the antitumour effects of IL21 and describe strategies to combine IL21 with other drugs for future cancer therapies.
- Kresten Skak
- Michael Kragh
- Pallavur V. Sivakumar